JP2018501287A5 - - Google Patents

Download PDF

Info

Publication number
JP2018501287A5
JP2018501287A5 JP2017536301A JP2017536301A JP2018501287A5 JP 2018501287 A5 JP2018501287 A5 JP 2018501287A5 JP 2017536301 A JP2017536301 A JP 2017536301A JP 2017536301 A JP2017536301 A JP 2017536301A JP 2018501287 A5 JP2018501287 A5 JP 2018501287A5
Authority
JP
Japan
Prior art keywords
group
alkyl
independently selected
heterocyclyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017536301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018501287A (ja
JP6659703B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/012659 external-priority patent/WO2016112298A1/en
Publication of JP2018501287A publication Critical patent/JP2018501287A/ja
Publication of JP2018501287A5 publication Critical patent/JP2018501287A5/ja
Application granted granted Critical
Publication of JP6659703B2 publication Critical patent/JP6659703B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017536301A 2015-01-09 2016-01-08 ピリダジノン誘導体および癌の処置におけるそれらの使用 Expired - Fee Related JP6659703B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562101953P 2015-01-09 2015-01-09
US62/101,953 2015-01-09
PCT/US2016/012659 WO2016112298A1 (en) 2015-01-09 2016-01-08 Pyridazinone derivatives and their use in the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2018501287A JP2018501287A (ja) 2018-01-18
JP2018501287A5 true JP2018501287A5 (enExample) 2019-01-31
JP6659703B2 JP6659703B2 (ja) 2020-03-04

Family

ID=55299747

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017536301A Expired - Fee Related JP6659703B2 (ja) 2015-01-09 2016-01-08 ピリダジノン誘導体および癌の処置におけるそれらの使用

Country Status (5)

Country Link
US (1) US10239861B2 (enExample)
EP (1) EP3242874B1 (enExample)
JP (1) JP6659703B2 (enExample)
CN (1) CN107406429B (enExample)
WO (1) WO2016112298A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3189049B1 (en) 2014-09-05 2024-03-20 Genentech, Inc. Phthalazine derivatives of formula (i) as pcaf and gcn5 inhibitors for use in the treatment of cancer
CN107074823B (zh) 2014-09-05 2021-05-04 基因泰克公司 治疗性化合物及其用途
KR102194536B1 (ko) * 2019-06-10 2020-12-23 연세대학교 산학협력단 타목시펜의 반응성 예측용 조성물
CN112824381B (zh) * 2019-11-21 2024-04-26 广东东阳光药业股份有限公司 一种哌啶胺的制备方法
CN116057045B (zh) 2020-06-05 2026-06-09 金耐特生物制药公司 成纤维细胞生长因子受体激酶抑制剂
WO2022076735A1 (en) * 2020-10-09 2022-04-14 Regents Of The University Of Minnesota Inhibitors of the bromodomain phd finger transcription factor (bptf) as anti-cancer agents
KR102766287B1 (ko) * 2021-10-15 2025-02-12 고려대학교 산학협력단 피리다벤을 포함하는 자궁내막 세포, 영양막 세포 또는 고환 세포의 비정상적 증식 관련 질환의 예방 또는 치료용 약학적 조성물
AU2023333181A1 (en) 2022-09-02 2025-03-13 Auron Therapeutics, Inc. Pyridazinon derivatives as kat2 degraders for the treatment of proliferative disorders

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
DE69025946T2 (de) 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
FR2707294B1 (fr) 1993-07-06 1995-09-29 Pf Medicament Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine.
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
ATE207366T1 (de) 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
KR100441557B1 (ko) 1994-07-21 2005-08-05 아크조 노벨 엔.브이. 고리형케톤과산화물조성물
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
PL188959B1 (pl) 1995-07-06 2005-05-31 Novartis Ag Pirolopirymidyny i sposoby ich wytwarzania
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU7165698A (en) 1997-05-06 1998-11-27 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
AU1308799A (en) 1997-11-06 1999-05-31 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
CN1160338C (zh) 1998-11-19 2004-08-04 沃尼尔·朗伯公司 N-[4-(3-氯-4-氟-苯基氨基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺,不可逆的酪氨酸激酶抑制剂
KR101190912B1 (ko) * 2003-11-19 2012-10-12 어레이 바이오파마 인크. Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
WO2006003147A1 (en) 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Phthalazine derivatives as parp inhibitors
JP2012131708A (ja) * 2009-04-28 2012-07-12 Nissan Chem Ind Ltd ４位置換ピリダジノン化合物及びｐ２ｘ７受容体阻害剤
JP2013528180A (ja) 2010-05-28 2013-07-08 ジーイー・ヘルスケア・リミテッド 放射性標識化合物及びその製造方法
UY35103A (es) 2012-10-29 2014-05-30 Glaxo Group Ltd Compuestos de cefem 2-sustituidos
JP2016507496A (ja) * 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
US9200005B2 (en) 2013-03-13 2015-12-01 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
CA2906100A1 (en) * 2013-03-15 2014-09-18 Genentech, Inc. Treating th2-mediated diseases by inhibition of bromodomains
CN107074823B (zh) 2014-09-05 2021-05-04 基因泰克公司 治疗性化合物及其用途
EP3189049B1 (en) 2014-09-05 2024-03-20 Genentech, Inc. Phthalazine derivatives of formula (i) as pcaf and gcn5 inhibitors for use in the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2019516757A5 (enExample)
JP2017530176A5 (enExample)
JP2017533250A5 (enExample)
JP2017526696A5 (enExample)
JP2019516759A5 (enExample)
JP2017537100A5 (enExample)
JP2018510851A5 (enExample)
JP2017533248A5 (enExample)
JP2017525740A5 (enExample)
JP2012510990A5 (enExample)
JP2024521706A5 (enExample)
JP2018505169A5 (enExample)
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
TWI373465B (en) Methods of administering pirfenidone therapy
JP2019529444A5 (enExample)
RU2020131507A (ru) Имидазопиперазиновые ингибиторы белков-активаторов транскрипции
JP2019510832A5 (enExample)
JP2013510123A5 (enExample)
JP2016510748A5 (enExample)
JP2016506916A5 (enExample)
JP2015500209A5 (enExample)
JP2017510641A5 (enExample)
HRP20171154T1 (hr) Kristalni inhibitori bromodomene
JP2018529742A5 (enExample)
JP2016516020A5 (enExample)